Novo Nordisk’s CagriSema, a next-generation weight-loss drug, has been dealt a significant setback after a head-to-head trial showed it to be less effective than Eli Lilly’s Zepbound, prompting analysts to speculate about the company’s future strategy, particularly in terms of mergers and acquisitions (M&A).
According to Reuters, the trial results have led analysts to question Novo Nordisk’s ability to compete with Eli Lilly in the obesity drug market. Michael Leuchten of Jefferies noted that the failure of CagriSema could lead investors to focus on Novo Nordisk’s M&A strategy, with potential for up to $35 billion to be spent this year.
Evan David Seigerman of BMO Capital Markets stated that there is no reason for a patient to be prescribed CagriSema over Tirzepatide, given the latter’s superior performance in the trial. Chris Schott of J.P. Morgan believes that the results confirm Zepbound as a clear market leader and position Eli Lilly for continued share gains.
Courtney Breen of Bernstein noted that the trial results emphasize Novo Nordisk’s challenges and Lilly’s continued dominance in the obesity drug market. James Gordon of Barclays stated that while CagriSema may still be approvable, driving uptake will be an uphill battle against a more effective and better-tolerated incumbent.
For more information on the pharmaceutical industry and the latest developments in obesity treatment, Bloomberg provides in-depth analysis and news coverage.
To stay up-to-date on the latest news and analysis, visit onlytrustedinfo.com for the most trusted and reliable information.
